BioArctic has entered a research collaboration with Eli Lilly to develop a new neurodegenerative disease treatment using BioArctic's BrainTransporter technology combined with a Lilly drug candidate. BioArctic will receive $30 million upfront and could earn up to $770 million in milestone payments plus royalties if the drug reaches the market. Lilly will handle global development and commercialization. This deal highlights the potential of BrainTransporter technology to improve drug delivery to the brain and marks BioArctic's fourth collaboration using this platform.
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
Eli Lilly reported a 55.5% revenue increase in Q1 to $19.8 billion, led by $8.66 billion from Mounjaro, and raised its full-year revenue guidance to $82-$85 billion. Despite strong fundamentals, the stock has been stuck near $1,100 due to concerns ov...
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...
Healthcare mergers and acquisitions surged to $65 billion in the first quarter of 2026, the highest since 2020, fueled by looming patent expirations on blockbuster drugs like Merck’s Keytruda. Pharma companies are acquiring innovative biotech firms t...
GLP-1 drugs for weight loss are rapidly expanding worldwide, with Novo Nordisk's Wegovy® pill reaching over three million prescriptions since January 2026 and launching in the UAE and UK. Eli Lilly's investigational drug retatrutide shows significant...
